Edgewise Therapeutics Doses First Participant In EQUINOX-HFpEF Study Of EDG-15400 To Treat Adults With Symptomatic Heart Failure With Preserved Ejection Fraction

Loading news article.

Edgewise Therapeutics Doses First Participant In EQUINOX-HFpEF Study Of EDG-15400 To Treat Adults With Symptomatic Heart Failure With Preserved Ejection Fraction | WAPE

Edgewise Therapeutics Doses First Participant In EQUINOX-HFpEF Study Of EDG-15400 To Treat Adults With Symptomatic Heart Failure With Preserved Ejection Fraction

Article summary

Related companies

Comments —